Ozempic (semaglutide, diabetes label) side effects
Ozempic's FDA label lists 5 common reactions, 8 serious warnings and 2 contraindications, plus a boxed warning. All of them are below in the label's own order; any percentage is the label's own figure, and nothing here is a recommendation.
No clinician has reviewed this page. Label and trial statements are quoted from the FDA label or the trial cited beside them. General guidance is marked as such, and every price carries the date it was verified. That is sourcing, not medical review. What we do and do not check · Who checked the price
Last updated 2026-06-10 — the version of the FDA label this page quotes. Read and dated by Alex Seot.
What are the side effects of Ozempic?
The FDA label for Ozempic lists nausea, vomiting, diarrhea, abdominal pain and constipation among the reactions reported in at least 5% of patients. It carries a boxed warning, the strongest the FDA issues: In rodents this molecule caused thyroid C-cell tumors at human-relevant doses. The label's serious warnings include acute pancreatitis; diabetic retinopathy complications; hypoglycemia with an insulin secretagogue or insulin; and acute kidney injury from volume depletion. It is contraindicated in 2 cases, among them a personal or family history of medullary thyroid carcinoma, or MEN 2, meaning the label says not to prescribe it at all. Every line above is quoted from FDA prescribing information for OZEMPIC (semaglutide) injection rather than summarized from a secondary source, because a side-effect list paraphrased twice stops being the label. That label version was published 2026-06-10. Frequencies are not repeated here second-hand: the percentage table lives in the label itself, which is linked on the page.
Boxed warning — the strongest warning the FDA issues
In rodents this molecule caused thyroid C-cell tumors at human-relevant doses. Whether it does so in people is unknown, and the label carries that as a boxed warning. It is contraindicated outright with a personal or family history of medullary thyroid carcinoma or MEN 2.
Common, and usually manageable
Reactions the label reports in at least 5% of patients.
- nausea
- vomiting
- diarrhea
- abdominal pain
- constipation
This is the diabetes label. Prescribed for weight loss it is off-label, which changes nothing about the side effects and everything about whether a plan will pay. Gastrointestinal reactions made 3.1% of patients stop at 0.5 mg and 3.8% at 1 mg, against 0.4% on placebo, and most nausea, vomiting and diarrhea came during dose escalation. Side effects that do not settle are a conversation with the prescriber rather than a reason to quit unannounced.
Serious, and worth knowing before you start
- Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back. The label says to stop the drug if it is suspected
- Diabetic retinopathy complications: 3.0% against 1.8% on placebo over two years, and 8.2% against 5.2% among those who already had retinopathy at baseline
- Never share a pen between patients, even with a new needle (5.4) — sharing risks passing on blood-borne infection
- Hypoglycemia with an insulin secretagogue or insulin: the label says the sulfonylurea or insulin dose may need lowering
- Acute kidney injury from volume depletion, in some cases needing dialysis, reported mostly in people who became dehydrated through nausea, vomiting or diarrhea
- Severe gastrointestinal reactions: 0.4% at 0.5 mg and 0.8% at 1 mg against 0% on placebo. Not recommended in severe gastroparesis
- Hypersensitivity reactions including anaphylaxis and angioedema, which the label says are a reason to stop and not to use it again
- Acute gallbladder disease: cholelithiasis in 1.5% at 0.5 mg and 0.4% at 1 mg, and in no placebo-treated patients
- Pulmonary aspiration during general anesthesia or deep sedation: the drug delays gastric emptying, and stomach contents have been found despite normal preoperative fasting. Tell any surgeon or anesthesiologist you are taking it
Who cannot take it
- A personal or family history of medullary thyroid carcinoma, or MEN 2
- Known hypersensitivity to semaglutide
Each of these, on its own
What the label says, why it happens, how it tracks the dose schedule and the point at which it stops being ordinary.
Everything on Ozempic
- Ozempic price and terms →
- What is Ozempic? →
- Ozempic cost without insurance →
- Alternatives to Ozempic →
- Ozempic coupons and savings cards →
- Ozempic and Wegovy cash price via GoodRx →
- Ozempic first-fill price →
- Ozempic Savings Card →
- Ozempic dose schedule →
- Can you stay on a lower dose of Ozempic? →
- How to inject Ozempic →
- How long Ozempic takes to work →
- Which labels record what happens when you stop →
- Hair loss: which of the labels name it →
- Alcohol: what the labels say, and what they do not →
- semaglutide at Calibrate: the price →
- semaglutide at LifeMD: the price →
- semaglutide at NovoCare Pharmacy: the price →
- semaglutide: every product and price →
- Foundayo vs Ozempic →
- Ozempic vs Wegovy pill →
- Compounded semaglutide vs Ozempic →
- Contrave vs Ozempic →
- Compounded tirzepatide vs Ozempic →
- Ozempic vs Phentermine →
- Ozempic vs Qsymia →
- Ozempic vs Wegovy →
- Mounjaro vs Ozempic →
- Ozempic vs Saxenda →
- Ozempic vs Zepbound →
- Ivim Health: the seller →
- Mochi Health: the seller →
- CVS MinuteClinic: the seller →
- Henry Meds: the seller →
- Noom Med: the seller →
- Shed: the seller →
- Walgreens Weight Management: the seller →
- PlushCare: the seller →
Questions
- What are the most common side effects of Ozempic?
- The label lists nausea, vomiting, diarrhea, abdominal pain, constipation among reactions reported in at least 5% of patients. The full frequency table is in the label itself, linked below; any percentage quoted on this page is the label's own figure.
- Who should not take it?
- The label contraindicates it in these cases: A personal or family history of medullary thyroid carcinoma, or MEN 2; Known hypersensitivity to semaglutide.
- What organ is Ozempic hard on?
- No single organ: Ozempic's FDA label warns about the pancreas, gallbladder, kidneys, eyes and stomach, and its boxed warning is about the thyroid. Pancreas — acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back. Gallbladder — acute gallbladder disease: cholelithiasis in 1.5% at 0.5 mg and 0.4% at 1 mg, and in no placebo-treated patients. Kidneys — acute kidney injury from volume depletion, in some cases needing dialysis, reported mostly in people who became dehydrated through nausea, vomiting or diarrhea. Eyes — diabetic retinopathy complications: 3.0% against 1.8% on placebo over two years, and 8.2% against 5.2% among those who already had retinopathy at baseline. Stomach — severe gastrointestinal reactions: 0.4% at 0.5 mg and 0.8% at 1 mg against 0% on placebo. Thyroid — the boxed warning: in rodents this molecule caused thyroid C-cell tumors at human-relevant doses; whether it does so in people is unknown.
- Do the side effects mean the price is not the issue?
- They meet at titration. Most of these reactions are worst in the weeks after a dose increase, and those are also the weeks when some sellers charge a lower starting price. So the months people are most likely to stop are not the months that show what the drug costs. The maintenance price is on the Ozempic price page.
Source: FDA prescribing information for OZEMPIC (semaglutide) injection, the version published 2026-06-10. Information only, not medical advice: a side effect you are having is a conversation with your prescriber, not with a comparison site.